Drugs / mRNA-4203
last change Jul 2025 re-read 2 minutes ago

mRNA-4203

Developed for
cutaneous melanoma · synovial sarcoma
Investigated by
Immatics US, Inc. · ModernaTX, Inc.

Trials 1 · a red edge is where a trial was stopped

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06946225 Jul 2025 → Aug 2029 expected cutaneous melanoma, synovial sarcoma Immatics US, Inc. Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as mRNA-4203 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06946225